Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Level of contact hypersensitivity response to diphencyprone and keratinocyte cancer.

Bullen A, Polcz M, Rowe CJ, Byrom L, Soyer HP, Khosrotehrani K.

J Eur Acad Dermatol Venereol. 2019 Nov;33(11):2101-2105. doi: 10.1111/jdv.15766. Epub 2019 Jul 19.

PMID:
31265155
2.

Topical immunotherapy with diphencyprone (DPCP) for in-transit and unresectable cutaneous melanoma lesions: an inaugural Canadian series.

Yeung C, Petrella TM, Wright FC, Abadir W, Look Hong NJ.

Expert Rev Clin Immunol. 2017 Apr;13(4):383-388. doi: 10.1080/1744666X.2017.1286984. Epub 2017 Feb 6.

PMID:
28121191
3.

Psoriasis is characterized by deficient negative immune regulation compared to transient delayed-type hypersensitivity reactions.

Gulati N, Suárez-Fariñas M, Correa da Rosa J, Krueger JG.

F1000Res. 2015 Jun 11;4:149. doi: 10.12688/f1000research.6581.1. eCollection 2015.

4.

Effects of acute, low-dose UVB radiation on the induction of contact hypersensitivity to diphenylcyclopropenone in man.

Friedli A, Hunziker T, Finkel B, Braathen LR.

Arch Dermatol Res. 1993;285(1-2):1-5.

PMID:
7682397
6.

Responses to Topical Diphenylcyclopropenone as an Adjunct Treatment for In-Transit Melanoma: A Tertiary Referral Center Experience.

Veverka KK, Jakub JW, Baum CL.

Dermatol Surg. 2018 Dec;44(12):1501-1508. doi: 10.1097/DSS.0000000000001603.

PMID:
29985863
7.

Anxiety and perceived psychological stress play an important role in the immune response after exercise.

Edwards JP, Walsh NP, Diment PC, Roberts R.

Exerc Immunol Rev. 2018;24:26-34.

8.

Efficacy and safety of diphenylcyclopropenone alone or in combination with anthralin in the treatment of chronic extensive alopecia areata: a retrospective case series.

Durdu M, Özcan D, Baba M, Seçkin D.

J Am Acad Dermatol. 2015 Apr;72(4):640-50. doi: 10.1016/j.jaad.2015.01.008. Epub 2015 Feb 1.

PMID:
25653027
9.

Topical diphencyprone immunotherapy for cutaneous metastatic melanoma.

Damian DL, Shannon KF, Saw RP, Thompson JF.

Australas J Dermatol. 2009 Nov;50(4):266-71. doi: 10.1111/j.1440-0960.2009.00556.x.

PMID:
19916970
10.

Diphencyprone Treatment of Alopecia Areata: Postulated Mechanism of Action and Prospects for Therapeutic Synergy with RNA Interference.

Bulock KG, Cardia JP, Pavco PA, Levis WR.

J Investig Dermatol Symp Proc. 2015 Nov;17(2):16-8. doi: 10.1038/jidsymp.2015.33.

11.

No adaptation to UV-induced immunosuppression and DNA damage following exposure of mice to chronic UV-exposure.

Steerenberg PA, Daamen F, Weesendorp E, Van Loveren H.

J Photochem Photobiol B. 2006 Jul 3;84(1):28-37. Epub 2006 Feb 28.

PMID:
16504533
12.

Diphenylcyclopropenone: examination for potential contaminants, mechanisms of sensitization, and photochemical stability.

Wilkerson MG, Henkin J, Wilkin JK.

J Am Acad Dermatol. 1984 Nov;11(5 Pt 1):802-7.

PMID:
6239880
13.

Alopecia areata in children: treatment with diphencyprone.

Schuttelaar ML, Hamstra JJ, Plinck EP, Peereboom-Wynia JD, Vuzevski VD, Mulder PG, Oranje AP.

Br J Dermatol. 1996 Oct;135(4):581-5.

PMID:
8915150
14.

Systemic immunogenicity of para-Phenylenediamine and Diphenylcyclopropenone: two potent contact allergy-inducing haptens.

Svalgaard JD, Særmark C, Dall M, Buschard K, Johansen JD, Engkilde K.

Immunol Res. 2014 Jan;58(1):40-50. doi: 10.1007/s12026-013-8482-z.

PMID:
24385090
15.

Sun protection for preventing basal cell and squamous cell skin cancers.

Sánchez G, Nova J, Rodriguez-Hernandez AE, Medina RD, Solorzano-Restrepo C, Gonzalez J, Olmos M, Godfrey K, Arevalo-Rodriguez I.

Cochrane Database Syst Rev. 2016 Jul 25;7:CD011161. doi: 10.1002/14651858.CD011161.pub2. Review.

16.

Topical immunotherapy with diphencyprone for in transit and cutaneously metastatic melanoma.

Damian DL, Saw RP, Thompson JF.

J Surg Oncol. 2014 Mar;109(4):308-13. doi: 10.1002/jso.23506. Epub 2013 Nov 19. Review.

PMID:
24522938
17.

Unique microRNAs appear at different times during the course of a delayed-type hypersensitivity reaction in human skin.

Gulati N, Løvendorf MB, Zibert JR, Akat KM, Renwick N, Tuschl T, Krueger JG.

Exp Dermatol. 2015 Dec;24(12):953-7. doi: 10.1111/exd.12813. Epub 2015 Aug 27.

18.

Diphencyprone induced vitiligo: a case report.

Nilforoushzadeh MA, Keshtmand G, Jaffary F, Kheirkhah A.

Case Rep Med. 2012;2012:356236. doi: 10.1155/2012/356236. Epub 2012 Jul 1.

20.

Squalene-containing nanostructured lipid carriers promote percutaneous absorption and hair follicle targeting of diphencyprone for treating alopecia areata.

Lin YK, Al-Suwayeh SA, Leu YL, Shen FM, Fang JY.

Pharm Res. 2013 Feb;30(2):435-46. doi: 10.1007/s11095-012-0888-0. Epub 2012 Oct 16.

PMID:
23070602

Supplemental Content

Support Center